OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by StockNews.com

OPKO Health (NASDAQ:OPK) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

OPK has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Trading Down 2.0 %

NASDAQ OPK opened at $1.48 on Tuesday. The stock has a market cap of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.76. The company has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.50.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 280,183 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the transaction, the chief executive officer now owns 211,512,405 shares in the company, valued at approximately $317,268,607.50. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 1,304,255 shares of company stock worth $2,024,605 over the last quarter. 47.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc grew its holdings in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares during the period. FMR LLC grew its stake in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the period. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health in the 3rd quarter worth $45,000. Algert Global LLC acquired a new position in OPKO Health during the second quarter worth $44,000. Finally, Private Advisor Group LLC lifted its holdings in OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.